Her har vi samlet et utvalg av studier som vi håper du kan ha nytte av i din behandling av pasienter med alvorlig allergisk astma

 

Humbert M, Taillé C, Mala L et al; «Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study” Eur Respir J. 2018 May 10;51(5)

 

Bousquet J, Brusselle G, Buhl R et al; “Care pathways for the selection of a biologic in severe asthma”, European Respiratory Journal 2017; 50: 170-178.

 

Humbert M, Beasley R, Ayres J et al; “Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE”, Allergy 2005;60:309-316.

 

Braunstahl G-J, Chen C-W, Maykut R et al; “The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma”, Respiratory Medicine 2013;107(8):1141-51.

 

Bousquet J, Siergiejko Z, Swiebocka E, et al; “Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma”, Allergy 2011 May:66:671-8

 

Korn S, Thielen A, Seyfried S et al; “Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany”, Resp Med 2009;103:1725–31

 

Braunstahl G-J, Canvin J, Peachey G et al; “Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting”, Biol Ther 2014; 4:57-67

 

NO1910749173
×

Medical Information Request

×

Ask Speakers